Ascendiant initiated coverage of Mira Pharmaceuticals with a Buy rating and $11 price target. The analyst sees large market opportunities for the comapny’s Ketamir-2 and MIRA-55 drugs for depression and dementia. The firm believes the start of clinical trials in late-2024/early-2025 will be “strong catalysts” for the stock.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRA:
- Mira Pharmaceuticals announces insights from additional Ketamir-2 data
- Mira Pharmaceuticals Inc trading resumes
- Mira Pharmaceuticals Inc trading halted, volatility trading pause
- Mira Pharmaceuticals announces preclinical results for Ketamir-2
- Mira Pharmaceuticals announces results for MIRA-55 in preclinical tess